Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Combination for GVHD Prevention in Children
NCT06475820Phase 3Active, not recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in graft-versus-host disease (GVHD), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Started Dec 2023; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06475820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475820.